Causeway Therapeutics
@causewaytx.bsky.social
We are The Tendon Health Company, a clinical-stage biotech developing novel medicines for tendon disease. www.causewaytx.com
Hear directly from our Co-Founders Derek Gilchrist, PhD, & Neal Millar, MD, PhD, about our new class of microRNA-based therapies with the potential to modify the disease at a molecular & structural level.
Check out the new video to learn more about TenoMiR®: bit.ly/48Cwf0K
Check out the new video to learn more about TenoMiR®: bit.ly/48Cwf0K
TenoMiR: A potentially groundbreaking treatment of tendinopathy
Causeway Therapeutics co-founders describe why TenoMiR has the potential to transform the treatment of tendinopathies.
bit.ly
December 2, 2025 at 2:54 PM
Hear directly from our Co-Founders Derek Gilchrist, PhD, & Neal Millar, MD, PhD, about our new class of microRNA-based therapies with the potential to modify the disease at a molecular & structural level.
Check out the new video to learn more about TenoMiR®: bit.ly/48Cwf0K
Check out the new video to learn more about TenoMiR®: bit.ly/48Cwf0K
#ICYMI, we debuted data from our Phase 2 trial of TenoMiR® in lateral epicondylitis, showing for the 1st time that a miR29a therapy relieves symptoms & improves tendon healing when correctly delivered into the tendinopathic lesion.
Read our release: bit.ly/4nC58IE
Read our release: bit.ly/4nC58IE
October 28, 2025 at 11:12 AM
#ICYMI, we debuted data from our Phase 2 trial of TenoMiR® in lateral epicondylitis, showing for the 1st time that a miR29a therapy relieves symptoms & improves tendon healing when correctly delivered into the tendinopathic lesion.
Read our release: bit.ly/4nC58IE
Read our release: bit.ly/4nC58IE
Excited to share @endpts.com’s coverage of our Phase 2 clinical data showing that when properly injected with a single dose of TenoMiR®, patients with lateral epicondylitis demonstrated statistically significant improvements in pain, function & tendon structure: bit.ly/3JnSgaT
Exclusive: Scottish microRNA startup claims signs of success in Phase 2 tendinopathy study
Causeway Therapeutics' microRNA drug for tennis elbow missed primary endpoint in Phase 2, but showed promise in properly injected patients. Plans Phase 3 amid $150M+ fundraising.
bit.ly
October 27, 2025 at 2:03 PM
Excited to share @endpts.com’s coverage of our Phase 2 clinical data showing that when properly injected with a single dose of TenoMiR®, patients with lateral epicondylitis demonstrated statistically significant improvements in pain, function & tendon structure: bit.ly/3JnSgaT
Did you know that each year more than 11 million people in the US experience symptoms of tendinopathy?
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
July 31, 2025 at 1:44 PM
Did you know that each year more than 11 million people in the US experience symptoms of tendinopathy?
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
We are developing treatments to address the molecular cause of tendon disease, not just alleviate symptoms.
Visit causewaytx.com to learn more.
Did you see Causeway’s new website?
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
June 4, 2025 at 1:20 PM
Did you see Causeway’s new website?
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
Check it out and sign up to learn more about forthcoming data announcements and clinical trials for our phase 2 clinical candidate, TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow): causewaytx.com
Meet Derek Gilchrist, PhD, Causeway’s Co-founder and Chief Science Officer. He leads the scientific development of TenoMiR®, a therapeutic now in a phase 2 clinical trial for patients with lateral epicondyle tendinopathy (tennis elbow). Learn more here: www.causewaytx.com
May 20, 2025 at 7:24 PM
Meet Derek Gilchrist, PhD, Causeway’s Co-founder and Chief Science Officer. He leads the scientific development of TenoMiR®, a therapeutic now in a phase 2 clinical trial for patients with lateral epicondyle tendinopathy (tennis elbow). Learn more here: www.causewaytx.com
We are delighted to launch the new Causeway website!
Sign up to learn more about forthcoming announcements and clinical trials for TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow).
Check it out here: causewaytx.com!
Sign up to learn more about forthcoming announcements and clinical trials for TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow).
Check it out here: causewaytx.com!
Causeway Therapeutics
The Tendon Health Company: Causeway Therapeutics is developing first-in-class microRNA therapies with the potential to improve quality of life for those suffering from tendinopathy.
causewaytx.com
May 8, 2025 at 2:15 PM
We are delighted to launch the new Causeway website!
Sign up to learn more about forthcoming announcements and clinical trials for TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow).
Check it out here: causewaytx.com!
Sign up to learn more about forthcoming announcements and clinical trials for TenoMiR®, a treatment for patients with lateral epicondylitis (tennis elbow).
Check it out here: causewaytx.com!
Our CEO Derek Gilchrist was recently featured in “Scrip Asks What Does 2025 Hold for Biopharma?” Check out the full article for Derek’s insights on how new approaches to microRNA delivery have the potential to target the root cause of disease: bit.ly/3FjJHvq
March 12, 2025 at 2:42 PM
Our CEO Derek Gilchrist was recently featured in “Scrip Asks What Does 2025 Hold for Biopharma?” Check out the full article for Derek’s insights on how new approaches to microRNA delivery have the potential to target the root cause of disease: bit.ly/3FjJHvq
#DidYouKnow that #tendinopathy impacts millions of people worldwide and costs health care systems billions of dollars per year?
Learn how Causeway is working to improve these outcomes with our #microRNA technology and lead candidate, TenoMIR, in a phase 2 trial for tennis elbow: bit.ly/4jw6ung
Learn how Causeway is working to improve these outcomes with our #microRNA technology and lead candidate, TenoMIR, in a phase 2 trial for tennis elbow: bit.ly/4jw6ung
Causeway Therapeutics
Developing miRNA therapeutics to treat common musculoskeletal diseases, such as osteoarthritis and tendinopathy, re-defining what old age looks and feels like
bit.ly
February 27, 2025 at 6:21 PM
#DidYouKnow that #tendinopathy impacts millions of people worldwide and costs health care systems billions of dollars per year?
Learn how Causeway is working to improve these outcomes with our #microRNA technology and lead candidate, TenoMIR, in a phase 2 trial for tennis elbow: bit.ly/4jw6ung
Learn how Causeway is working to improve these outcomes with our #microRNA technology and lead candidate, TenoMIR, in a phase 2 trial for tennis elbow: bit.ly/4jw6ung